Compare LPTH & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | LBRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.1M | 602.6M |
| IPO Year | 2011 | N/A |
| Metric | LPTH | LBRX |
|---|---|---|
| Price | $11.80 | $24.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.33 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 2.8M | 185.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $81.01 | N/A |
| Revenue Next Year | $25.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $1.61 | $13.40 |
| 52 Week High | $15.24 | $25.60 |
| Indicator | LPTH | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 56.98 |
| Support Level | $11.03 | $22.48 |
| Resistance Level | $13.76 | $24.70 |
| Average True Range (ATR) | 1.27 | 1.29 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 46.78 | 65.59 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.